Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

Published:
September 19, 2023
Written by

View More News

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

January 29, 2025

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs

January 29, 2025
View News Article

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

January 29, 2025

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

BioLoomics’ goal is to make a degrader from an antibody in one month

January 29, 2025
View News Article

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

January 29, 2025

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

Our mission is to make safer, more effective cancer therapeutics.

January 29, 2025
View News Article
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.